TMCnet News
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor EventsBASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April: LD Micro Invitational XIV (April 8-9, 2024) Register for Webcast: https://ldinv14.sequireevents.com/ Management will be available for one-on-one meetings with registered investors of the conference. Please reach out to the Lisata representative under the contact section below or Dean Summers at LD Micro ([email protected]) to register for the event and schedule a meeting with the Company. FORCE Family Office Webinar with Lisata Therapeutics (April 10, 2024) Webinar details will be provided upon RSVP approval. To register for the event, please visit www.forcefamilyoffice.com/events/healthcare/isata-therapeutics-coming-april-10-2024 Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (April 17-18, 2024) Management will be available for one-on-one meetings with registered investors of the conference. Please reach out to the Lisata representative under the contact section below or [email protected] to register for the event and schedule a meeting with the Company. For more information on the event, please visit https://bit.ly/3VwVxbz. Immuno-Oncology Summit Europe (April 23-25, 2024) To register for the event, please visit www.immuno-oncologyeurope.com. About Lisata Therapeutics Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com. Contact: Investors and Media: Lisata Therapeutics, Inc.
|
